Clinical Trial Update: A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) [Phase 3]

View source ↗

Summary

Phase 3 REACH3 trial comparing ruxolitinib to best available therapy for steroid-refractory chronic graft-versus-host disease after allogeneic stem cell transpl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Graft-versus-host Disease (GVHD) | Phase 3 | Status: COMPLETED | Results posted: 2022-04-15